The recombinant oncolytic adenovirus OAV-TRIM56 exhibits enhanced replication and antitumor activity, supporting the concept that targeting host factors to promote OAV replication is a promising strategy for optimizing oncolytic adenovirus therapy in cancer treatment. Here, TRIM56 is linked to cancer.